Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities
Please select the market sector you are interested in.
Please select the university you are interested in.
Show only Easy Access opportunities.
Narrow your search with a few keywords.
University: University of St Andrews
Sector(s): Life Sciences
In vitro tests show that using an echinocandin drug with an antimicrobial peptide provides a synergistic combination for treating a fungal infection.
Combination therapy potentially offers a new route to targeting fungal infections, including those caused by highly resistant fungi (e.g. Candida glabrata)Combination therapy leads to less drug resistance compared to single use drugs.Synergistic activity in combination therapy allows lower concentrations of expensive echinocandin drugs to be used, reducing potential toxicity and side effects and the cost of treatment
Echinocandin drugs (caspofungin, micafungin & anidulafungin) are first-line antifungal treatments for Candida and Aspergillus infections, but have limited effect on a broader range of fungal infections. Combination therapy could widen the applications for echinocandin drugs and lead to better, lower cost therapies for patients.
A UK patent application was filed on 18 September 2008, application number 0817121.7. This has been followed by PCT application PCT/GB2009/002226 in 2009.
Easy Access Documents:
Please enter your name.
Please enter the name of the company you work for.
Is your company an SME?
Please select the country you are in.
Please select what part of the UK you are in.
Please select from the following options.
Please enter your email address.
Please enter your telephone number.
To help us process your enquiry faster please enter some details about the information you are interested in.
Please prove you are a human by completing this simple image recognition task.
University of Glasgow scientists have borrowed techniques employed in the semi-conductor industry to pattern the surfaces of either hard or soft materials and render these surfaces less adhesive to cells.
The new treatment is a combination of a peptide (ranalexin) with bacteria cell wall-digesting protein (lysostaphin), which specifically targets and kills Staphylococcus aureus, including MRSA.
Combining the sequential use of 2 enzymes – fluorinase and nucleoside hydrolase – we have successfully produced a new radiotracer with potential as an imaging biomarker for PET scans. The fluorinase enzyme combines fluorine with S-adenosyl-L-methionine (SAM) to generate 5'-fluro-5'-deoxy...
mCBMs are engineered multivalent proteins based on the sialic acid (SA)-recognising carbohydrate-binding module (CBM40) derived from bacterial sialidases. Engineered mCBMs have potential as biological agents in respiratory disease by masking cell surface sialic acid receptors.
Based on their importance in health and disease, the proteases of the endo-lysosomal pathway - particularly the cathepsins - have frequently been proposed as therapeutic targets. Effective pharmaceutical exploitation of the pathway has been prevented by the issue of redundancy - novel methods to ove...